Investment
Features
FeesSafety
Academy
More
Pluang+

Orchid Island Capital declares April dividend of $0.10/share, reports Q1 2026 net loss and portfolio update.

Company Fundamentals
15 Apr 2026
GlobeNewsWire
View Source
Neutral
pluang ai news

Orchid Island Capital announced a monthly dividend of $0.10 per share for April 2026, payable on May 28, 2026. The company reported an estimated net loss of $0.11 per share for Q1 2026, mainly due to $0.37 per share in net realized and unrealized losses on RMBS and derivatives. Its estimated book value per share stood at $7.08 as of March 31, 2026, with a total return on equity of -1.3% for the quarter. Orchid Island plans to continue regular monthly dividends, with the next announcement expected on May 13, 2026, while providing detailed RMBS portfolio characteristics as part of its financial update.

More News

Sodexo wins major global catering contract with Meta for 130+ sites in 30+ countries

Sodexo wins major global catering contract with Meta for 130+ sites in 30+ countries

Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...

Market News
Bullish
3 hours ago
Thor Explorations stays on track with gold production and strong cash position in Q2 2026.

Thor Explorations stays on track with gold production and strong cash position in Q2 2026.

Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...

Company Fundamentals
Bullish
4 hours ago
Angelini Pharma completes $4.1B acquisition of Catalyst, expanding US presence and brain health leadership.

Angelini Pharma completes $4.1B acquisition of Catalyst, expanding US presence and brain health leadership.

Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...

Company Fundamentals
Bullish
4 hours ago
Zcash surges 16% ahead of Ironwood upgrade, eyes $644 resistance as key next target

Zcash surges 16% ahead of Ironwood upgrade, eyes $644 resistance as key next target

Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...

Protocol Fundamentals
Bullish
4 hours ago
Greenwich LifeSciences' breast cancer drug shows strong Phase 2 results but faces funding risks ahead of Phase 3.

Greenwich LifeSciences' breast cancer drug shows strong Phase 2 results but faces funding risks ahead of Phase 3.

Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App